Calcium Gluconate

Summary

Calcium Gluconate (CHEMBL2106119) is an approved small-molecule nutraceutical (ATC B05XA19); indicated across 5 conditions including osteoporosis and ovarian hyperstimulation syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05XA19 (+2 more)
• Indications: 5 conditions
• Clinical trials: 20
• Chemistry: 430.37 Da · C12H22CaO14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106119
Name	Calcium Gluconate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9290
ChEBI	CHEBI:3309
ATC	B05XA19, A12AA03, D11AX03
Molecular formula	C12H22CaO14
Molecular weight	430.37
InChIKey	NEEHYRZPVYRGPP-IYEMJOQQSA-L

SMILES: C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Ca+2]

IUPAC name: calcium bis((2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate)

ChEBI definition: The calcium salt of D-gluconic acid.

Pharmacological roles (ChEBI): nutraceutical.

Also known as: Calcarea gluconica, Calcii gluconas, Calcium d-gluconate monohydrate, Calcium di-gluconate, Calcium gluconate, Calcium gluconate anhydrous, Calcium gluconate hydrate, Calcium gluconate in sodium chloride, Calcium gluconate monohydrate, anhydrous, Calglucon, E-578

Patent coverage: 14,195 distinct patent families (34,787 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoporosis	3	MONDO:0005298	EFO:0003882
ovarian hyperstimulation syndrome	2	MONDO:0011972	MONDO:0011972
peripheral nervous system disorder	1	MONDO:0003620	EFO:0004149

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	4
Not specified	4
PHASE1	2
PHASE4	1
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04491357	PHASE4	UNKNOWN	Prophylactic Infusion of Calcium Gluconate Reducing the Rate of Hypocalcaemia After Total Thyroidectomy
NCT06820645	PHASE2/PHASE3	NOT_YET_RECRUITING	Calcium Administration in Life-saving Management During Massive Hemorrhage
NCT00058188	PHASE3	TERMINATED	Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
NCT00316914	PHASE3	COMPLETED	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
NCT00354302	PHASE3	COMPLETED	Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
NCT00998738	PHASE3	TERMINATED	Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
NCT01099449	PHASE3	COMPLETED	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
NCT03473613	PHASE3	COMPLETED	Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
NCT05953376	PHASE3	WITHDRAWN	Empiric Calcium in Massive Transfusion
NCT05958342	PHASE2	RECRUITING	CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
NCT07217899	PHASE2	RECRUITING	Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony
NCT00416715	PHASE2	COMPLETED	Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
NCT02875587	PHASE2	COMPLETED	Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome
NCT01682499	PHASE1	COMPLETED	Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy
NCT04958044	PHASE1	COMPLETED	Endoscopic Assisted Calcium Electroporation in Esophageal Cancer
NCT05973747	EARLY_PHASE1	COMPLETED	Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients
NCT06235749	Not specified	RECRUITING	Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery
NCT00004361	Not specified	COMPLETED	Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects
NCT02580604	Not specified	COMPLETED	PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)
NCT06333691	Not specified	COMPLETED	Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).